Immunic Inc. appointed Erik Lundgren as its chief executive officer on Wednesday to lead the company through late-stage drug development.
The leadership change occurs as the firm prepares for the potential commercialization of a new therapy. This transition is critical because the company is moving its primary candidate for treating multiple sclerosis (MS) into Phase 3 trials [1].
Lundgren brings experience from his previous tenure as an executive at Genentech. The company said the appointment is intended to strengthen leadership while the MS pipeline moves through the final stages of development [1], [2].
Phase 3 trials [1] represent the final stage of clinical testing before a pharmaceutical company can seek regulatory approval to market a drug. Success in these trials is necessary to prove the safety and efficacy of the treatment in a large patient population.
Immunic is now positioning its internal operations to handle the shift from a research-focused entity to a commercial provider. This involves scaling the infrastructure needed to bring the MS therapy to market if the trials yield positive results [1], [2].
“Immunic Inc. appointed Erik Lundgren as its chief executive officer on Wednesday.”
The appointment of a former Genentech executive suggests that Immunic is prioritizing commercial scale and regulatory experience. By installing a leader with a background in large-scale biotech operations just as it enters Phase 3 trials, the company is signaling a shift from early-stage discovery to the high-stakes process of market entry and product launch.
